Coenzyme Q10 supplementary therapy in patients is based on its antioxidant and reenergization effects. CoQ10 has been successfully used in clinical medicine as a supplementary therapy in several diseases: in patients with mitochondrial neuromuscular diseases, neurodegenerative diseases (Parkinson’s, dementias), cardiovascular diseases (congestive heart failure, cardiomyopathy), statins therapy, chronic fatique syndrom, nephropathy, cancer –breast treatment, chemotheraphy amelioration, diabetes mellitus, bronchial asthma, infertile men, sports medicine, stress and ageing. Bioavailability, dosage and duration of CoQ10 treatment are important factors for human tissue uptake and beneficial effect of administered CoQ10.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gvozdjáková A, Kucharská J, Hlavatá A, Braunová Z, Reichrtová E, Kajglová A, Kapellerová A (2000) Effect of coenzyme Q10 in children with metabolic diseases. J Am Coll Nutr 19(5): Abstract 117, p 704. The American College of Nutrition’s 41st Annual Meeting, Las Vegas, USA, 12–15 October 2000 (Prize award)
References
Gazdíková K, Gvozdjáková A, Kucharská J, Spustová V, Braunová Z, Dzúrik R (2000) Malondialdehyde and selected antioxidant plasma levels in conservatively treated patients with kidney diseases. BMJ 101:490–494
Gazdíková K, Gvozdjáková A, Kucharská J, Spustová V, Braunová Z, Dzúrik R (2001) Effect of coenzyme Q10 in patients with kidney disease. Čas Lek Česk 140:307–310 (in Slovak)
Gazdíková K, Gvozdjáková A, Kucharská J, Spustová V, Braunová Z, Dzúrik R (2001) Oxidative stress and plasma concentrations of coenzyme Q10, alpha-tocopherol, and beta-carotene in patients widh a mild to moderate decrease of kidney function. Nephron 88(3):285
Gvozdjáková A (2000) Coenzyme Q10 (experimental study). Effects of hydrosoluble, liposoluble and reduced coenzyme Q10 forms in aged rats. Tishcon Corp. USA: Project, 2000, Part 6, Kidney Mitochondria: P6/4–P17 tables and figures
Gvozdjáková A, Gazdíková K, Kucharská J, Spustová V, Braunová Z, Dzúrik R (2000) The effect of coenzyme Q10 in patients with nephropathies. J Am Coll Nutr 19(5):708. American College of Nutrition, 41st Annual Meeting, Las Vegas, 12–15 October 2000, Abstract 132
Gvozdjáková A., Gazdíková K, Kucharská J, Spustová V, Braunová Z, Dzúrik R (2000) Deficit of coenzyme Q10 in patients with nephropathies and beneficial effect of supplementary therapy with coenzyme Q10. The Second Conference of the International Coenzyme Q 10 Association, Frankfurt, Germany, 2000, December 1–4, abstract book pp 111–112
Lippa S, Colacicco L, Calla C, Gozzo ML, Ciccariello M, Angelitti AG (1994) Coenzyme Q10 levels, plasma lipids and peroxidation extent in renal failure and in hemodialytic patients. Mol Aspects Med 15 Supplement:213–219
References
Gazdík F, Gvozdjáková A, Nádvorníková R, Repická L, Jahnová J, Kucharská J, Pijak MR, Gazdíková K (2002) Decreased levels of coenzyme Q10 in patients with bronchial asthma. Allergy 57:811–814
Gvozdjáková A, Kucharská J, Bartkovjaková M, Gazdíková K, Gazdík F (2005a) Coenzyme Q10 supplementation reduces corticosteroid dosage in patients with asthma bronchiale. Fourth Conference of the International Coenzyme Q 10 Association, Los Angeles, 2005, Abstract book pp 108–109
Gvozdjáková A, Kucharská J, Bartkovjaková M, Gazdíková K, Gazdík F (2005b) Coenzyme Q10 supplementation reduces corticosteroid dosage in patients with asthma bronchiale. BioFactors 25:235–240
Gvozdjáková A (2006) Asthma, corticosteroids and coenzyme Q10. http://www.vitasearch.com/get/PC/experts/AGvozdjakovaAT10–02-06.htm
Kinulla V (2005) Production and degradation of oxygen metabolites during inflammatory states in the human lung. Curr Drug Targets Inflamm Allergy 4(4):465–470
References
Cadenas E, Packer L (1996) (eds) Handbook of Antioxidants. Marcel Dekker, NY, pp 545–591
Foster TS (2007) Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomathic diabetic neuropathy. Diabetes Educa 33(1):111–117
Gvozdjáková A, Palacka P, Kucharská J, Okkelová A, Murín J (2007) Beneficial effect of simultaneous coenzyme Q10 and -lipoic acid supplementation in patients with diabetic cardiomyopathy. Fifth Conference of the International Coenzyme Q 10 Association, Kobe, Japan, November 9–12, 2007, No. JP-051
Murray MT (1996) Encyclopedia of Nutritional Supplements. Prima Publishing, Rocklin, CA, pp 243–346
Packer L, Tritschler HJ, Wesssel K (1997) Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 22(1–2):359–378
Reljanivic M, Reichel C et al. (1999) Treatment of diabetic peripheral neuropathy with the antioxidant thioctic acid (alpha-lipoic acid). A two tier multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res 31:171–179
Ziegler D, Hanefeld M et al. (1995) Treatment of symtomatic diabetic peripheral neuropathy with antioxidant alpha-lipoic acid. A 3-week multicentral randomized controlled trial (ALADIN Study). Diabetologia 38:1425–1433
Ziegler D, Hanefeld M et al. (1999) Treatment of symtomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 22:1296–1301
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media B.V
About this chapter
Cite this chapter
Gvozdjáková, A., Hlavatá, A., Kucharská, J., Palacka, P., Murín, J. (2008). Coenzyme Q10 Supplementation in Clinical Medicine. In: Gvozdjáková, A. (eds) Mitochondrial Medicine. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6714-3_17
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6714-3_17
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6713-6
Online ISBN: 978-1-4020-6714-3
eBook Packages: MedicineMedicine (R0)